Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation - Colman, Rebecca E.; Mace, Aurélien; Seifert, Marva; Hetzel, Jonathan; Mshaiel, Haifa; Suresh, Anita; Lemmer, Darrin; Engelthaler, David M.; Catanzaro, Donald G.; Young, Amanda G.; Denkinger, Claudia M.; Rodwell, Timothy C. (PLoS medicine, 2019)
Keywords: Antitubercular agents; Bioinformatics; Capital costs; Clinical isolates; Complexity; Computational biology; Consortia; Control; Cost-Benefit Analysis; Deoxyribonucleic acid; Diagnostic reagents; DNA; DNA sequencing; DNA, Bacterial - analysis; Drug resistance; Drug Resistance, Multiple, Bacterial - genetics; Evaluation; Genetic aspects; Genome-wide association studies; Genomes; Genomic libraries; Genomics; Health surveillance; High-Throughput Nucleotide Sequencing - economics; High-Throughput Nucleotide Sequencing - instrumentation; High-Throughput Nucleotide Sequencing - methods; High-throughput screening (Biochemical assaying); Humans; Infectious diseases; Instrumentation; Laboratories; Maintenance costs; Medical research; Medicine; Microbial drug resistance; Mortality; Mutation; Mycobacterium tuberculosis; Mycobacterium tuberculosis - genetics; Next-generation sequencing; Occupational health; Optimization; Patients; Public health; Reproducibility of Results; Risk factors; Sequence Analysis, DNA - economics; Sequence Analysis, DNA - instrumentation; Sequence Analysis, DNA - methods; Single-nucleotide polymorphism; Time Factors; Tuberculosis; Tuberculosis, Multidrug-Resistant - microbiology; Visualization; Whole genome sequencing; Workflow; Workflow software; California; United States--US; Switzerland; Arizona